You are here

Generic Cancer Drug Cleared for Marketing

DUBLIN, Calif., Nov 15, 2004 /PRNewswire-FirstCall via COMTEX/ -- SuperGen, Inc. (Nasdaq: SUPG) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Paclitaxel Injection, 6 mg/mL, packaged in 30 mg/5 mL and 100 mg/16.7 mL multiple-dose vials.

Paclitaxel belongs to the group of medicines called antineoplastics. The drug is equivalent to Bristol-Myers Squibb's Taxol(R) Injection; an antitumor agent that has become one of the most widely used anti-cancer products.

Paclitaxel Injection's approved indication is identical to Taxol(R) and is indicated as treatment for a variety of cancers.

"FDA approval of our ANDA to market Paclitaxel in the U.S. is a significant accomplishment for SuperGen," stated James Manuso, Ph.D., President and Chief Executive Officer. "We are currently in discussions with several U.S. multi-source generic manufacturers specializing in oncology and hope to complete a marketing and distribution licensing agreement during the first half of 2005."

Source: SuperGen, Inc.

Recent Headlines

Almost 64% of Patients Showed Decreased Hemoglobin A1c Levels
Lifesaving Life Foam for Battlefield, Terrorist Attacks, Trauma
Cell Reprogramming Process May Benefit Patients Prone to Severe Hypoglycemia
Beagles Beat Out Advanced Technology
Over Half of Patients Had Reduced Pain Levels of 30% or More
Spina Bifida, Cleft Lip Among Defects Caused by Antiepilectics
Study Data Indicate Drug May Provide Complete Remission in PV
Teplizumab Slows Progression to Disease by at Least Two 2 Years
Over 25% of Study Patients Showed 6–12 Months Remission